Sartorius Stedim Biotech acquires UK-based CRO, BioOutsource
Takeover expands SSB’s service portfolio
Sartorius Stedim Biotech (SSB) acquired the Scottish company BioOutsource Ltd. The privately owned company based in Glasgow, UK, has been operating in the biotechnology market since 2007, and in the last twelve months earned revenue of around 9 million euros with approx. 85 employees. The contractual parties agreed not to disclose any further details of the transaction.
BioOutsource provides contract testing services to global biopharmaceutical clients in order to monitor the safety and quality of biologic drugs and vaccines. In particular, the company specializes in offering a comprehensive suite of services for the fast growing biosimilar industry. Its assays are used in the early phases of drug characterization and comparability and for lot release testing of novel therapeutics. This acquisition will develop SSB’s service offering throughout the drug development pathway.
Reinhard Vogt, member of SSB’s Board, commented, “By adding contract testing services, we will be able to support our biopharma clients even better in their drive to fast-track their new drug candidates through the development and clinical test phases and facilitate lot release testing in large scale manufacturing. The highly qualified team at BioOutsource will ideally complement our expertise, and we are looking forward to working with them.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
